In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $14.24 down -4.94% from its previous closing price of $14.98. In other words, the price has decreased by -$4.94 from its previous closing price. On the day, 0.98 million shares were traded. AMLX stock price reached its highest trading level at $14.91 during the session, while it also had its lowest trading level at $14.165.
Ratios:
For a deeper understanding of Amylyx Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.70 and its Current Ratio is at 13.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17. On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when Bedrosian Camille L bought 6,580 shares for $14.35 per share.
Klee Justin B. sold 29,975 shares of AMLX for $430,952 on Sep 30 ’25. The Co-Chief Executive Officer now owns 3,325,301 shares after completing the transaction at $14.38 per share. On Sep 30 ’25, another insider, Mazzariello Gina, who serves as the Chief Legal Officer of the company, sold 8,828 shares for $14.58 each. As a result, the insider received 128,669 and left with 148,141 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1563830656 and an Enterprise Value of 1225775616. Its current Enterprise Value per Revenue stands at -1843.272 whereas that against EBITDA is -7.819.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.33, which has changed by 1.8 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $16.96, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is 2.11%, while the 200-Day Moving Average is calculated to be 76.55%.
Shares Statistics:
For the past three months, AMLX has traded an average of 1.80M shares per day and 1430180 over the past ten days. A total of 109.77M shares are outstanding, with a floating share count of 91.06M. Insiders hold about 17.08% of the company’s shares, while institutions hold 94.46% stake in the company. Shares short for AMLX as of 1763078400 were 11911669 with a Short Ratio of 6.61, compared to 1760486400 on 9616175. Therefore, it implies a Short% of Shares Outstanding of 11911669 and a Short% of Float of 11.74.
Earnings Estimates
The stock of Amylyx Pharmaceuticals Inc (AMLX) is currently drawing attention from 8.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.26 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.26 and -$1.79 for the fiscal current year, implying an average EPS of -$1.57. EPS for the following year is -$1.24, with 8.0 analysts recommending between -$0.76 and -$1.64.
